LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Tiny $35M Biotech Leverages Proven Technology to Potentially Revolutionize How Diabetes and Obesity Medications Are Delivered (NASDAQ:PYPD)PolyPid ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...

Trump’s latest two industrial sector tariffs—200 percent on pharmaceuticals and 50 percent on copper—have serious ...

Here are the Cincinnati Enquirer's 2025 high school All-Star / all-city teams for Southwest Ohio, Northern Kentucky and ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...